Patent application number | Description | Published |
20090181030 | USE OF A PREPARATION BASED ON AN ANTIBODY DIRECTED AGAINST A TUMOR-ASSOCIATED GLYCOSYLATION - The invention relates to the use of a preparation based on an antibody directed against a tumor-associated glycosylation for preparing a medicament for the prophylactic and/or therapeutic treatment for the reduction or inhibition, respectively, of the growth of tumor cells in a cancer patient, as well as to a pharmaceutical preparation containing an antibody directed against a tumor-associated glycosylation. Moreover, the invention relates to a preparation for pharmaceutical and/or diagnostic use, a diagnostic method and an agent for determining the risk of metastasis formation in a cancer patient, as well as a method of producing a preparation based on a body fluid or tissue, in each case using the antibody directed against a tumor-associated glycosylation. | 07-16-2009 |
20100233178 | USE OF ANTIBODIES FOR THE VACCINATION AGAINST CANCER - Described is the use of antibodies which are directed against human cellular membrane antigens for the vaccination against cancer diseases. | 09-16-2010 |
20100310551 | IMMUNOGENIC, MONOCLONAL ANTIBODY - The invention relates to an immunogenic antibody which comprises at least two different epitopes of a tumor-associated antigen. | 12-09-2010 |
20100316624 | TREATMENT OF FIBROSES AND LIVER DISORDERS - The present invention relates to ACE2 for the therapeutic treatment or prevention of a fibrosis or liver disorder. | 12-16-2010 |
20110020315 | TREATMENT OF INFLAMMATORY ILLNESSES WITH ACE2 - The present invention relates to ACE2 for the therapeutic treatment or prevention of inflammation. | 01-27-2011 |
20110020331 | N-GLYCOSYLATED ANTIBODY - The invention relates to a monoclonal antibody or derivative or fragment thereof that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region or region equivalent to the Fc region of said antibody or derivative or fragment thereof carries a bi-sected hybrid type N-glycosylation pattern and that said antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity. | 01-27-2011 |
20110033524 | TREATMENT OF TUMORS - The invention provides for innovative improvements in tumour therapy, particularly therapies which are conducted using endogenous substances and which have no or only mild side-effects. Accordingly the present invention relates to methods of treating or preventing tumor diseases other than lung cancer comprising administering a polypeptide with an angiotensin-converting-enzyme-2 (ACE2) activity. | 02-10-2011 |
20120003232 | USE OF ANTIBODIES FOR THE VACCINATION AGAINST CANCER - Described is the use of antibodies which are directed against human cellular membrane antigens for the vaccination against cancer diseases. | 01-05-2012 |
20140010781 | SIRNA AGAINST CBL-B AND OPTIONALLY IL-2 AND IL-12 FOR USE IN THE TREATMENT OF CANCER - The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus permits the therapy of appropriate diseases. | 01-09-2014 |
Patent application number | Description | Published |
20090130125 | COMBINATION OF TUMOR-ASSOCIATED SURFACE PROTEIN ANTIGENS AND TUMOR-ASSOCIATED SUGARS IN THE TREATMENT AND DIAGNOSIS OF CANCER - The invention relates to a kit for the combined use for the treatment of cancer patients, which set comprises an antigen of a cellular surface protein, or an antibody directed against the cellular surface protein, and an antigen of an aberrant glycosylation, or an antibody directed against the aberrant glycosylation. This kit is destined both for the immunotherapeutic and the diagnostic application. The invention further relates to a selection method for selecting suitable tumor-specific antigens with the assistance of this kit and corresponding specific antibody preparations. | 05-21-2009 |
20100028932 | GENERAL PROGNOSTIC PARAMETERS FOR TUMOUR PATIENTS - Described is a method for identifying the prognosis for improved clinical benefit of an individual suffering from a tumor comprising providing a blood sample of said individual, (a1) determining the number of lymphocytes in the blood of said individual, and/or (a2) determining the number of neutrophils in the blood of said individual, and (b1) identifying the individual as having a good prognosis for improved clinical benefit, if the number of lymphocytes is above a lymphocyte baseline level of 1.4 to 1.8×10 | 02-04-2010 |
20100086570 | CANCER IMMUNOTHERAPY PREDICTIVE PARAMETERS - The invention relates to a method for predicting the efficacy of a cancer immunotherapy of an individual with respect to clinical benefit, which comprises the following steps: —providing a blood sample of said individual, —(a1) determining the number of lymphocytes in the blood of said individual, and/or (a2) determining the number of neutrophils in the blood of said individual, and —(b1) identifying the individual as having a predictive clinical benefit from the immunotherapy, if the number Of lymphocytes is below or equal to a lymphocyte baseline level of 1.4 to 1.8×10 | 04-08-2010 |
20100260808 | Method for Increasing Immunoreactivity - The invention relates to an in vitro or ex vivo method for increasing the immunoreactivity of cells of the immune system, which were contacted with an antigen, said method comprising the reduction or inhibition of the Cbl-b function of said cells, thereby increasing the immunoreactivity of the cells towards the antigen. | 10-14-2010 |
20100261214 | Method for Determining ACE2 Activity - The present invention relates to a method of determining ACE2 activity, comprising the following steps: providing ACE2-binding units immobilized on a solid carrier and specific for a part of ACE2 which is not involved in the catalytic activity of ACE2; contacting the immobilized ACE2-binding units with a sample which potentially includes the ACE2, wherein the ACE2 is bound by the ACE2-binding unit; removing the non-binding portions of the sample from the ACE2 bound to the ACE2-binding units; adding a substrate of the ACE2 which is reacted by the ACE2 activity, with the reaction providing a signal; and measuring the change in the signal during a specific period of time, wherein the change can be correlated with the ACE2 activity. | 10-14-2010 |
20100310546 | ACE2 Polypeptide - The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life. | 12-09-2010 |
20120040864 | Method for Determining the Cbl-b Expression - The present invention relates to methods of determining intracellular Cbl-b protein in cells of a sample, comprising
| 02-16-2012 |
20140099297 | ACE2 POLYPEPTIDE - The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life | 04-10-2014 |
20140170155 | Method for Treating a GD2 Positive Cancer - Preparations and methods for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2), and wherein one or more treatment periods with the antibody may be preceded, accompanied, and/or followed by one or more treatment periods with a retinoid. | 06-19-2014 |
20140322308 | Compositions for Preventing or Treating Adverse Reactions of EGFR Inhibition - The invention discloses a pharmaceutical composition comprising recombinant human superoxide dismutase (rhS-OD) for preventing or treating one or more adverse reactions caused by treatment with an EGFR inhibitor in a subject. | 10-30-2014 |
20150050676 | Method for Measurement of Peptidic Degradation Products of a Proteolytic Cascade in Blood Samples - The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade (for example, the renin-angiotensin system (RAS) and the bradykinin system) in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample. | 02-19-2015 |